Company Monitoring Page for Alkermes

job ratings for Alkermes

04/28/23
industry:
Bio pharmaceutical Industry
company:
Alkermes
job rating:
7
I get to use my unique knowledge and background every day. Relaxed and collegial interactions with all.
06/25/20
industry:
Bio pharmaceutical Industry
company:
Alkermes
job rating:
7
Great people and noble goal
11/06/19
industry:
Biotech/Pharmaceutical
company:
Alkermes
job rating:
7
Culture and Team
01/04/17
industry:
Biotech
company:
Alkermes
job rating:
1
It's acting like big pharma. I was told we were a biotech company but that is far from the truth.

latest headlines for company on cafepharma

Alkermes reports data from Phase Ib narcolepsy treatment trial
Clinical Trials Arena
Wed, 04/10/24 - 06:00 pm
Tags:
Alkermes, clinical trials, narcolepsy, ALKS 2680
Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios
BioSpace
Tue, 03/12/24 - 11:02 am
Tags:
Alkermes, Jazz Pharma, Neuroscience, oncology
With good news on Lybalvi, Alkermes sees 10% share price increase
Fierce Pharma
Fri, 02/16/24 - 11:21 am
Tags:
Alkermes, Lybalvi, schizophrenia, biopolar disorder
JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company
Fierce Pharma
Wed, 01/10/24 - 09:44 am
Tags:
Alkermes, JPMHC 2024
Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience
BioSpace
Wed, 11/15/23 - 11:58 am
Tags:
Alkermes, spinoffs, oncology, Mural Oncology, NASDAQ
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680
Drugs.com
Tue, 10/10/23 - 11:47 pm
Tags:
Alkermes, ALKS 2680, narcolepsy
Alkermes fends off generic versions of Vivitrol until 2027
Clinical Trials Arena
Thu, 08/31/23 - 06:07 pm
Tags:
Alkermes, Teva Pharmaceutical, Vivitrol, patents, legal
Alkermes, nearing oncology split, posts big Q2 sales gain after winning J&J arbitration case
Fierce Pharma
Wed, 07/26/23 - 06:37 pm
Tags:
JNJ, Alkermes, oncology, earnings
Sarissa Capital urges Alkermes shareholders to vote for its board nominees after years of rejections
Fierce Pharma
Mon, 06/12/23 - 10:21 am
Tags:
Alkermes, Sarissa Capital
Alkermes, after arbitration win over J&J, jacks up revenue forecast by $425M
Fierce Pharma
Wed, 06/7/23 - 10:18 am
Tags:
Alkermes, JNJ, nanocrystals
Alkermes to hive off oncology business
Pharma Letter
Thu, 11/3/22 - 10:55 am
Tags:
Alkermes, oncology, spinoffs
With millions on the line, Alkermes, J&J start arbitration over drug delivery tech dispute
Fierce Pharma
Fri, 04/22/22 - 10:32 am
Tags:
Alkermes, JNJ, Janssen, drug delivery, Nanocrystal
J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'
Endpoints
Tue, 11/9/21 - 11:35 pm
Tags:
JNJ, Alkermes, nanoparticles
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Motley Fool
Sun, 06/13/21 - 10:44 pm
Tags:
Biogen, Alkermes, Alpine Immune Sciences
ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus
EP Vantage
Fri, 06/4/21 - 10:41 am
Tags:
ASCO 2021, Alkermes, melanoma, nemvaleukin alfa
After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi
Pharmaforum
Thu, 06/3/21 - 10:37 am
Tags:
Alkermes, FDA, antipsychotic, Lybalvi
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
Biopharma Dive
Tue, 06/1/21 - 10:37 pm
Tags:
Alkermes, FDA, schizophrenia, bipolar disorder, Lybalvi
As Alkermes shines light on early cancer, neuro assets, biotech searches for collabs, strategic ops
Fierce Biotech
Fri, 03/26/21 - 10:47 am
Tags:
Alkermes, R&D, cancer, immuno-oncology
Why Alkermes' Q4 Results Were Better Than They Might Seem
Motley Fool
Thu, 02/11/21 - 10:25 pm
Tags:
Alkermes, earnings
Alkermes sees swift turnaround for rejected schizophrenia med as FDA accepts resubmission
Fierce Biotech
Tue, 12/29/20 - 10:51 am
Tags:
Alkermes, ALKS 5461, ALKS 3831, FDA, drug manufacturing, schizophrenia

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.